Inmazeb

Inmazeb. It is a fixed-dose combination of three monoclonal antibodies—atoltivimab, maftivimab, and odesivimab—used for the treatment of infection caused by the Zaire ebolavirus. Developed by the biotechnology company Regeneron Pharmaceuticals, it represents a significant advancement in the therapeutic arsenal against Ebola virus disease. The treatment received approval from the U.S. Food and Drug Administration in October 2020 following a pivotal clinical trial conducted during an outbreak in the Democratic Republic of the Congo.

Medical uses

Inmazeb is indicated for the treatment of infection caused by the Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is positive for the virus. It is not indicated for other species within the Ebolavirus genus, such as the Sudan virus or the Bundibugyo virus. Administration occurs via intravenous infusion in a healthcare setting equipped to manage the severe complications of the disease. The approval was based on data from the PALM trial, a randomized controlled study conducted in partnership with the World Health Organization and the National Institute of Allergy and Infectious Diseases, which demonstrated superior survival rates compared to other investigational therapies.

Adverse effects

The most common adverse reactions associated with Inmazeb include fever, chills, tachycardia, tachypnea, vomiting, hypotension, and diarrhea. These symptoms are often difficult to distinguish from the manifestations of Ebola virus disease itself. Serious infusion-related reactions, such as anaphylaxis, are possible, necessitating close monitoring during and after administration. Given the severity of the underlying condition, the FDA determined that the demonstrated survival benefit outweighed these potential risks, a conclusion supported by data reviewed by the agency's Antimicrobial Drugs Advisory Committee.

Pharmacology

Inmazeb is a combination of three human IgG1 monoclonal antibodies that bind to non-overlapping epitopes on the glycoprotein of the Zaire ebolavirus. This multi-targeted approach is designed to neutralize the virus and block its entry into host cells, leveraging mechanisms similar to other antiviral monoclonal antibody cocktails like REGN-COV2 for COVID-19. The pharmacokinetic profile supports a single-dose regimen, with the antibodies exhibiting a half-life that provides sustained viral neutralization. The development utilized Regeneron's proprietary VelocImmune technology platform, which was also instrumental in creating treatments for conditions like macular degeneration and certain cancers.

History

The development of Inmazeb was accelerated in response to the devastating West African Ebola virus epidemic and subsequent outbreaks in the Democratic Republic of the Congo. The pivotal PALM trial was initiated in 2018 under the coordination of an international consortium that included the WHO, the NIAID, and the Institut National de Recherche Biomédicale in Kinshasa. In October 2020, the FDA granted approval under the agency's Animal Rule, as human efficacy studies were unethical and unfeasible, relying instead on robust evidence from animal models and supportive human safety data. This approval marked the first for a treatment targeting the Zaire ebolavirus.

Society and culture

The approval of Inmazeb was hailed as a landmark achievement in the fight against Ebola virus disease, a illness that has caused significant mortality and social disruption in regions like West Africa. Its development underscores the critical role of public-private partnerships, involving entities like the Biomedical Advanced Research and Development Authority and the Wellcome Trust. The treatment's availability is managed through strategic stockpiling by organizations such as the World Health Organization for deployment during outbreaks. Its success has influenced regulatory pathways for other infectious disease threats and highlighted the importance of platform technologies like those used by Regeneron Pharmaceuticals for rapid response. Category:Monoclonal antibodies Category:Antiviral drugs Category:Ebola